First-line combination therapy with rituximab and corticosteroids is effective and safe for pemphigus.

作者信息

Cho Yung-Tsu, Lee Fang-Yu, Chu Chia-Yu, Wang Li-Fang

机构信息

Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, 15 F, No.7, Chung-Shan S. Rd., Taipei 10002, Taiwan.

出版信息

Acta Derm Venereol. 2014 Jul;94(4):472-3. doi: 10.2340/00015555-1746.

DOI:10.2340/00015555-1746

PMID:24217821

Abstract

摘要

相似文献

First-line combination therapy with rituximab and corticosteroids is effective and safe for pemphigus.

Acta Derm Venereol. 2014 Jul;94(4):472-3. doi: 10.2340/00015555-1746.

Management of pemphigus in pediatric patients.

Minerva Pediatr. 2011 Aug;63(4):279-91.

Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients.

Dermatology. 2011;223(2):182-8. doi: 10.1159/000332848. Epub 2011 Oct 21.

Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris.

J Am Acad Dermatol. 2011 Nov;65(5):1064-5. doi: 10.1016/j.jaad.2010.06.033.

[Autoimmune blistering skin diseases: diagnostic and therapeutic approach].

Dtsch Med Wochenschr. 2014 Jul;139(28-29):1473-7. doi: 10.1055/s-0034-1370151. Epub 2014 Jul 1.

Refractory pemphigus vulgaris treated with rituximab and mycophenolate mofetil.

An Bras Dermatol. 2014 Nov-Dec;89(6):980-4. doi: 10.1590/abd1806-4841.20143128.

Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up.

J Am Acad Dermatol. 2012 Oct;67(4):623-9. doi: 10.1016/j.jaad.2011.12.019. Epub 2012 Jan 20.

Current therapy of the pemphigus group.

Clin Dermatol. 2012 Jan-Feb;30(1):84-94. doi: 10.1016/j.clindermatol.2011.03.014.

The actual management of pemphigus.

G Ital Dermatol Venereol. 2010 Oct;145(5):689-702.

Concurrent cytomegalovirus and herpes simplex virus infection in pemphigus vulgaris treated with rituximab and prednisolone.

Acta Derm Venereol. 2013 Mar 27;93(2):200-1. doi: 10.2340/00015555-1429.

引用本文的文献

Efficacy and safety of low dose rituximab in pemphigus: an updated systematic review and meta-analysis.

Front Immunol. 2025 Jul 25;16:1605243. doi: 10.3389/fimmu.2025.1605243. eCollection 2025.

Current biologics in treatment of pemphigus foliaceus: a systematic review.

Front Immunol. 2023 Oct 12;14:1267668. doi: 10.3389/fimmu.2023.1267668. eCollection 2023.

Immunocytometric Analysis of Oral Pemphigus vulgaris Patients after Treatment with Rituximab as Adjuvant.

Biomolecules. 2021 Nov 4;11(11):1634. doi: 10.3390/biom11111634.

Rituximab Therapy for Treatment of Pemphigus in Southeast Asians.

Drug Des Devel Ther. 2021 Apr 22;15:1677-1690. doi: 10.2147/DDDT.S306046. eCollection 2021.

Rituximab: A Magic Bullet for Pemphigus.

J Clin Diagn Res. 2017 Apr;11(4):WC01-WC06. doi: 10.7860/JCDR/2017/21868.9717. Epub 2017 Apr 1.

Rituximab therapy improves recalcitrant Pemphigus vulgaris.

EXCLI J. 2015 Jan 21;14:109-16. doi: 10.17179/excli2014-603. eCollection 2015.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

First-line combination therapy with rituximab and corticosteroids is effective and safe for pemphigus.

Acta Derm Venereol. 2014 Jul;94(4):472-3. doi: 10.2340/00015555-1746.

Management of pemphigus in pediatric patients.

Minerva Pediatr. 2011 Aug;63(4):279-91.

Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients.

Dermatology. 2011;223(2):182-8. doi: 10.1159/000332848. Epub 2011 Oct 21.

Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris.

J Am Acad Dermatol. 2011 Nov;65(5):1064-5. doi: 10.1016/j.jaad.2010.06.033.

[Autoimmune blistering skin diseases: diagnostic and therapeutic approach].

Dtsch Med Wochenschr. 2014 Jul;139(28-29):1473-7. doi: 10.1055/s-0034-1370151. Epub 2014 Jul 1.

Refractory pemphigus vulgaris treated with rituximab and mycophenolate mofetil.

An Bras Dermatol. 2014 Nov-Dec;89(6):980-4. doi: 10.1590/abd1806-4841.20143128.

Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up.

J Am Acad Dermatol. 2012 Oct;67(4):623-9. doi: 10.1016/j.jaad.2011.12.019. Epub 2012 Jan 20.

Current therapy of the pemphigus group.

Clin Dermatol. 2012 Jan-Feb;30(1):84-94. doi: 10.1016/j.clindermatol.2011.03.014.

The actual management of pemphigus.

G Ital Dermatol Venereol. 2010 Oct;145(5):689-702.

Concurrent cytomegalovirus and herpes simplex virus infection in pemphigus vulgaris treated with rituximab and prednisolone.

Acta Derm Venereol. 2013 Mar 27;93(2):200-1. doi: 10.2340/00015555-1429.

引用本文的文献

Efficacy and safety of low dose rituximab in pemphigus: an updated systematic review and meta-analysis.

Front Immunol. 2025 Jul 25;16:1605243. doi: 10.3389/fimmu.2025.1605243. eCollection 2025.

Current biologics in treatment of pemphigus foliaceus: a systematic review.

Front Immunol. 2023 Oct 12;14:1267668. doi: 10.3389/fimmu.2023.1267668. eCollection 2023.

Immunocytometric Analysis of Oral Pemphigus vulgaris Patients after Treatment with Rituximab as Adjuvant.

Biomolecules. 2021 Nov 4;11(11):1634. doi: 10.3390/biom11111634.

Rituximab Therapy for Treatment of Pemphigus in Southeast Asians.

Drug Des Devel Ther. 2021 Apr 22;15:1677-1690. doi: 10.2147/DDDT.S306046. eCollection 2021.

Rituximab: A Magic Bullet for Pemphigus.

J Clin Diagn Res. 2017 Apr;11(4):WC01-WC06. doi: 10.7860/JCDR/2017/21868.9717. Epub 2017 Apr 1.

Rituximab therapy improves recalcitrant Pemphigus vulgaris.

EXCLI J. 2015 Jan 21;14:109-16. doi: 10.17179/excli2014-603. eCollection 2015.